SynthesisFrontiers in drug safety and regulation2026
Risk of neurodevelopmental disorders after fetal topiramate exposure: a systematic review.
Synthesis in Frontiers in drug safety and regulation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Recent studies suggest an association between fetal topiramate exposure and an increased risk of neurodevelopmental disorders (NDD), such as autism spectrum disorders (ASD), intellectual disability (ID) and attention deficit hyperkinetic disorder (ADHD). This systematic review aimed to evaluate the evidence for such an association. Methods: A systematic literature search was conducted in Medline, Cochrane, and Embase on 16 December 2024, with automatic updates running until submission. Articles were examined if they included any number of offsprings of persons with epilepsy of childbearing potential (PWECP) exposed to topiramate during pregnancy. The main comparison was offspring of pregnant people without epilepsy and no antiseizure medication use, or alternatively antiseizure medication apart from topiramate. The search was limited to English language articles 2014-2024. The study followed PRISMA guidelines for reporting. Results: 14 studies were included. The number of topiramate-exposed children ranged from 2 to 1,000. Most studies had a small group exposed to topiramate, and a large control group. Seven studies found a relationship between NDD outcomes and topiramate, three studies found no increased risk, and four studies were inconclusive. However, the risk seems mainly to be increased relative to no ASM use, and in many studies the risk was similar for lamotrigine and seemed lower than for valproate. Methodological approaches varied. Eleven studies were considered to be of good or fair quality, whereas three studies were considered to be of poor quality. Conclusion: This systematic review shows that topiramate prescribing requires caution in PWECP and that topiramate use during pregnancy warrants special attention to the neurodevelopment of the child. The risk seems to be increased relative to no ASM use, is not necessarily higher than the risk for lamotrigine, and lower than the risk of valproate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.